Clinical Trial Update: A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care [Phase 3]

View source ↗

Summary

Phase 3 trial of GLPG1690 in idiopathic pulmonary fibrosis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• GLPG1690 (GLPG1690)

Snippet

Sponsor: Galapagos NV | Conditions: Idiopathic Pulmonary Fibrosis | Phase 3 | Status: TERMINATED | Results posted: 2022-07-29